$ Value
$0
Shares
575
Price
$0
Filed
Feb 18
Insider
Name
Mulholland Kristen
Title
EVP, Chief HR Officer
CIK
0002037288
Roles
Transaction Details
Transaction Date
2026-02-15
Code
M
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
20,081
Footnotes
Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 13, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. | Shares withheld for payment of taxes upon vesting of RSUs. | Performance Share Units (PSUs) awarded under Issuer's Long-Term Incentive Plan on February 13, 2023. The PSUs convert into shares of Common Stock upon vesting. | Shares withheld for payment of taxes upon vesting of PSUs. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSU convert into shares of Common Stock upon vesting. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis. | Each RSU represents a contingent right to receive one share of Company Common Stock. | Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date. | Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.
Filing Info
Mulholland Kristen's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | F | $42K |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | F | $61K |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | M | $0 |
| 2026-02-15 | JNJ | A | $0 |
| 2026-02-15 | JNJ | A | $0 |
| 2026-02-13 | JNJ | M | $0 |
| 2026-02-13 | JNJ | F | $33K |
Other Insiders at JNJ (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
REED JOHN C
EVP, Innovative Medicine, R&D
|
— | $13.1M | 2026-02-17 |
|
Duato Joaquin
CEO and Chairman of the Board
|
— | $22.1M | 2026-02-15 |
|
Wolk Joseph J
Exec VP, CFO
|
— | $21.8M | 2026-02-17 |
|
Taubert Jennifer L
EVP, WWC. Innovative Medicine
|
— | — | 2026-02-15 |
|
Wengel Kathryn E
EVP, Chief TO and Risk Officer
|
— | — | 2026-02-15 |
|
Decker Robert J
VP Corporate Controller
|
— | $1.0M | 2026-02-27 |
|
Swanson James D.
EVP, CIO
|
— | $15.1M | 2026-02-17 |
|
Broadhurst Vanessa
EVP, Global Corp Affairs
|
— | $1.5M | 2026-02-17 |
|
Forminard Elizabeth
EVP, Chief Legal Officer
|
— | — | 2026-02-15 |
|
Schmid Timothy
EVP, WW Chair, MedTech
|
— | $5.9M | 2026-02-20 |
|
Mulholland Kristen
EVP, Chief HR Officer
|
— | — | 2026-02-15 |